Michael J Mitchell
Overview
Explore the profile of Michael J Mitchell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
176
Citations
6604
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Safford H, Shuler C, Geisler H, Thatte A, Swingle K, Han E, et al.
Nano Lett
. 2025 Mar;
PMID: 40084657
It is well established that the physicochemical properties of lipid nanoparticles (LNPs) can govern their interactions with various biological barriers. One property hypothesized to influence nanoparticle-cell interactions is elasticity. Here,...
2.
Han X, Xu Y, Ricciardi A, Xu J, Palanki R, Chowdhary V, et al.
bioRxiv
. 2025 Mar;
PMID: 40060499
mRNA-based gene editing therapeutics offer the potential to permanently cure diseases but are hindered by suboptimal delivery platforms. Here, we devise a robust combinatorial chemistry for plug-and-play assembly of diverse...
3.
Swingle K, Hamilton A, Safford H, Geisler H, Thatte A, Palanki R, et al.
Nature
. 2025 Feb;
638(8051):E33.
PMID: 39900626
No abstract available.
4.
Padilla M, Mrksich K, Wang Y, Haley R, Li J, Han E, et al.
Nat Commun
. 2025 Jan;
16(1):996.
PMID: 39856035
Lipid nanoparticles (LNPs) are the preeminent non-viral drug delivery vehicle for mRNA-based therapies. Immense effort has been placed on optimizing the ionizable lipid (IL) structure, which contains an amine core...
5.
Arnaout S, Stock S, Clifford J, Greenough T, Wedig A, Mitchell M, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofae751.
PMID: 39834750
Background: Blood culture contaminants can lead to inappropriate antibiotic use, prolonged length of stay, and additional hospital costs. Several devices have been developed to reduce the risk of blood culture...
6.
Padilla M, Padilla M, Shepherd S, Hanna A, Kurnik M, Zhang X, et al.
bioRxiv
. 2025 Jan;
PMID: 39763759
Lipid nanoparticles (LNPs) are the most advanced delivery system currently available for RNA therapeutics. Their development has accelerated since the success of Patisiran, the first siRNA-LNP therapeutic, and the mRNA...
7.
Xue L, Xiong X, Zhao G, Molina-Arocho W, Palanki R, Xiao Z, et al.
J Am Chem Soc
. 2025 Jan;
147(2):1542-1552.
PMID: 39742515
Lipid nanoparticles (LNPs) have emerged as pivotal vehicles for messenger RNA (mRNA) delivery to hepatocytes upon systemic administration and to antigen-presenting cells following intramuscular injection. However, achieving systemic mRNA delivery...
8.
Hwang Y, Shepherd S, Kim D, Mukalel A, Mitchell M, Issadore D, et al.
ACS Nano
. 2024 Dec;
19(1):1090-1102.
PMID: 39700475
Despite the numerous advantages demonstrated by microfluidic mixing for RNA-loaded lipid nanoparticle (RNA-LNP) production over bulk methods, such as precise size control, homogeneous distributions, higher encapsulation efficiencies, and improved reproducibility,...
9.
Han E, Tang S, Kim D, Murray A, Swingle K, Hamilton A, et al.
Nano Lett
. 2024 Dec;
25(2):800-810.
PMID: 39688915
Systemic delivery of large nucleic acids, such as mRNA, to the brain remains challenging in part due to the blood-brain barrier (BBB) and the tendency of delivery vehicles to accumulate...
10.
Sanati M, Figueroa-Espada C, Han E, Mitchell M, Yavari S
ACS Nano
. 2024 Dec;
18(51):34425-34463.
PMID: 39666006
Chemoresistance remains a long-standing challenge after cancer treatment. Over the last two decades, RNA interference (RNAi) has emerged as a gene therapy modality to sensitize cancer cells to chemotherapy. However,...